Wang, Dongdong http://orcid.org/0000-0002-6195-4428
Day, Emily A. http://orcid.org/0000-0003-3245-5715
Townsend, Logan K.
Djordjevic, Djordje http://orcid.org/0000-0003-3669-6292
Jørgensen, Sebastian Beck http://orcid.org/0000-0002-9648-0971
Steinberg, Gregory R. http://orcid.org/0000-0001-5425-8275
Article History
Accepted: 17 June 2021
First Online: 11 August 2021
Competing interests
: D.D. and S.B.J. are employees of Novo Nordisk A/S, a pharmaceutical company producing and selling medicine for the treatment of diabetes and obesity. G.R.S. is a co-founder and shareholder of Espervita Therapeutics, a company developing new medications for liver cancer. McMaster University has received funding from Espervita Therapeutics, Esperion Therapeutics, Poxel Pharmaceuticals and Novo Nordisk for research conducted in the laboratory of G.R.S. G.R.S. has received consulting/speaking fees from Astra Zeneca, Eli Lilly, Esperion Therapeutics, Merck, Poxel Pharmaceuticals and Takeda. The other authors declare no competing interests.